Idiotype vaccines for human B-cell malignancies

Current Pharmaceutical Design
Susana InogesMaurizio Bendandi

Abstract

After twenty years of use in humans, customized idiotypic vaccination yet remains a non-approved, experimental therapeutic option for patients with lymphoma and myeloma. Potentially applicable to all B-cell malignancies whose cells express a clonal immunoglobulin or its epitopes on their surface, this treatment is designed to prevent disease recurrence or progression. Mostly used in follicular lymphoma patients so far, idiotype vaccines have clearly shown biological efficacy, clinical efficacy and clinical benefit in this setting, although no study aiming at regulatory approval of the procedure has been able to meet its main clinical endpoints. In mantle cell lymphoma, only biological efficacy has been proven for idiotypic vaccination, while in multiple myeloma a limited number of studies support the notion of biological and perhaps even clinical efficacy, although no credible evidence of clinical benefit has still emerged. Idiotype vaccines have been produced and administered in a number of substantially different manners. Therefore, the results of most clinical trials cannot be easily compared, and even less pooled together in meaningful meta-analyses. A more creative and yet scientifically sound way to design clinical trials...Continue Reading

Citations

Jul 21, 2011·World Journal of Clinical Oncology·Susana InogesMaurizio Bendandi
Aug 18, 2012·Leukemia & Lymphoma·Ascensión López-Díaz de CerioMaurizio Bendandi
Jul 20, 2012·Critical Reviews in Oncology/hematology·Mauro CivesFranco Silvestris
Mar 15, 2010·Pharmaceuticals·Maurizio Bendandi
Jun 23, 2011·Expert Review of Vaccines·Susana InogésMaurizio Bendandi
Oct 10, 2015·Leukemia·O A HaabethB Bogen
Nov 17, 2011·Expert Review of Vaccines·Helena VillanuevaMaurizio Bendandi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Expert Review of Vaccines
Susana InogesMaurizio Bendandi
Current Hematologic Malignancy Reports
Shibichakravarthy Kannan, Sattva S Neelapu
Current Topics in Medicinal Chemistry
Susana InogesMaurizio Bendandi
© 2021 Meta ULC. All rights reserved